AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25548329 — intervention group
Group type: COMPARATOR
Intervention: Written reminder-only
Number of subjects: 660
Study 23208525 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous vitamin C (HDVC) 200 mg/kg/day for 10 days plus oral vitamin C 2000 mg for 30 days after discharge
Number of subjects: 72
Study 23208525 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid treatment for 15 days
Number of subjects: 72
Study 22234000 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg IV
Number of subjects: 338
Study 22234000 — intervention group
Group type: COMPARATOR
Intervention: ketoprofen 100 mg IV
Number of subjects: 338
Study 19238488 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline with behavioral smoking cessation treatment
Number of subjects: 1117
Study 17445101 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Treatment (ET) with almotriptan 12.5 mg, treated at earliest onset of headache pain (within 1 hour)
Number of subjects: 1450
Study 17445101 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST) with almotriptan 12.5 mg, treated when headache pain intensity is moderate or severe
Number of subjects: 1450
Study 17445101 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Treatment (ET) subgroup treating headache pain within 1 hour of onset
Number of subjects: 1450
Study 17445101 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST) subgroups treating within 1 hour versus greater than 1 hour after headache onset
Number of subjects: 1450
Study 17445101 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in Early Treatment (ET) group
Number of subjects: 1450
Study 17445101 — intervention group
Group type: COMPARATOR
Intervention: Adverse events in Standard Treatment (ST) group
Number of subjects: 1450
Study 15329068 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid (VPA)
Number of subjects: 38
Study 15329068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 38
Study 12566649 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 0
Study 12566649 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI (balloon)
Number of subjects: 0
Study 12566649 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI (stent)
Number of subjects: 0
Study 12566649 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 0
Study 11229251 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical CPAP (Group A)
Number of subjects: 28
Study 11229251 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcritical CPAP (Group B)
Number of subjects: 28
Study 8087439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Cancer Symptom Scale (LCSS) administered at baseline, day 29, and day 71
Number of subjects: 144
Study 2767747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal pentazocine (0, 1, 2, 3, 4, and 5 mg) along with 1% bupivacaine
Number of subjects: 60
Study 2767747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal pentazocine (3 mg)
Number of subjects: 60
Study 2767747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal pentazocine (higher doses)
Number of subjects: 60
Study 271411 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris-clip lens implantation
Number of subjects: 0
Study 271411 — intervention group
Group type: COMPARATOR
Intervention: Simple cataract extraction
Number of subjects: 0
Study 30996338 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search training (minimum 30 min, 5 days/week over 6 weeks)
Number of subjects: 87
Study 30996338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresnel prisms (minimum 2 hours, 5 days/week over 6 weeks)
Number of subjects: 87
Study 30996338 — intervention group
Group type: COMPARATOR
Intervention: Standard care - information only
Number of subjects: 87
Study 30080227 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=44), 60 minutes/session, twice per week for 24 weeks
Number of subjects: 91
Study 30080227 — intervention group
Group type: COMPARATOR
Intervention: Social-based activities (n=47), 60 minutes/session, twice per week for 24 weeks
Number of subjects: 91
Study 26210894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-3 years of maintenance Bacillus Calmette-Guérin (BCG) after transurethral resection of the bladder (TURB) and induction BCG
Number of subjects: 1812
Study 26210894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-3 years of maintenance Bacillus Calmette-Guérin (BCG)
Number of subjects: 1812
Study 24096920 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation exercises followed by didactic lecture
Number of subjects: 29
Study 24096920 — intervention group
Group type: COMPARATOR
Intervention: Simulation after lecture
Number of subjects: 29
Study 21645945 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session for physicians (Group 1)
Number of subjects: 4076
Study 21645945 — intervention group
Group type: COMPARATOR
Intervention: No training session for physicians (Group 2)
Number of subjects: 4076
Study 21645945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined population (Groups 1 + 2)
Number of subjects: 4076
Study 20442758 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days on/2 days off treatment
Number of subjects: 146
Study 20442758 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment
Number of subjects: 146
Study 17363764 — intervention group
Group type: EXPERIMENTAL
Intervention: Message from a low credibility source before the target message
Number of subjects: 0
Study 17363764 — intervention group
Group type: COMPARATOR
Intervention: Message from a high credibility source before the target message
Number of subjects: 0
Study 17363764 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with a dissimilarity mindset before the target message
Number of subjects: 0
Study 17363764 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with a similarity mindset before the target message
Number of subjects: 0
Study 15786795 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (educational brochure + motivational interview)
Number of subjects: 80
Study 15786795 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 12034036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon-alpha2b (1 million IU) with didanosine
Number of subjects: 68
Study 12034036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose interferon-alpha2b (10 million IU) with didanosine
Number of subjects: 68
Study 12034036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose interferon-alpha2b
Number of subjects: 68
Study 12034036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose and intermediate-dose interferon-alpha2b
Number of subjects: 68
Study 12034036 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4 count
Number of subjects: 68
Study 10024260 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention (graphical displays of prescribing rates and educational newsletters)
Number of subjects: 2440
Study 10024260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 2440
Study 8584481 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine with food
Number of subjects: 20
Study 8584481 — intervention group
Group type: COMPARATOR
Intervention: Zalcitabine without food (fasting)
Number of subjects: 20
Study 1973352 — intervention group
Group type: EXPERIMENTAL
Intervention: H0 model
Number of subjects: 0
Study 1973352 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical data
Number of subjects: 0
Study 406875 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (ergot derivative)
Number of subjects: 0
Study 406875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31340089 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 154
Study 31340089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 28911749 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory women's groups and counselling through home visits
Number of subjects: 3001
Study 28911749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3001
Study 25305572 — intervention group
Group type: EXPERIMENTAL
Intervention: V mode electrothermal energy
Number of subjects: 101
Study 25305572 — intervention group
Group type: COMPARATOR
Intervention: cut/coag electrothermal energy
Number of subjects: 101
Study 23473369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 11145
Study 23473369 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11145
Study 21600563 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Ritual Prevention (EX/RP) treatment for OCD, 17 sessions over 8 weeks
Number of subjects: 49
Study 21600563 — intervention group
Group type: EXPERIMENTAL
Intervention: OCPD diagnosis
Number of subjects: 49
Study 21600563 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfectionism (OCPD criterion)
Number of subjects: 49
Study 19694112 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR (Interactive Voice Response) technology, 11 automated calls over 6 months
Number of subjects: 331
Study 19694112 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 331
Study 19694112 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR (Interactive Voice Response) technology
Number of subjects: 331
Study 16467232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (40% of participants, n = 19,541)
Number of subjects: 48835
Study 16467232 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (60% of participants, n = 29,294)
Number of subjects: 48835
Study 16467232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (adherent women)
Number of subjects: 48835
Study 16467232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (high-fat diet at baseline)
Number of subjects: 48835
Study 16467232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (tumor hormone receptor characteristics)
Number of subjects: 48835
Study 15271196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox shampoo 1%
Number of subjects: 499
Study 15271196 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 499
Study 11005044 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective forms of ECT
Number of subjects: 57
Study 11005044 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage right unilateral ECT
Number of subjects: 57
Study 11005044 — intervention group
Group type: COMPARATOR
Intervention: Low dosage right unilateral ECT
Number of subjects: 57
Study 11005044 — intervention group
Group type: COMPARATOR
Intervention: Generalized seizure expression
Number of subjects: 57
Study 9217347 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing Self‐Concept workshop
Number of subjects: 74
Study 9217347 — intervention group
Group type: COMPARATOR
Intervention: Control group (information sessions)
Number of subjects: 74
Study 7923712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 51
Study 7923712 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study 3528889 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (2.4 to 9.9 g/day)
Number of subjects: 18
Study 3528889 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam combined with phosphatidylcholine (PC) (18 g/day)
Number of subjects: 18
Study 3528889 — intervention group
Group type: COMPARATOR
Intervention: Phosphatidylcholine (PC) alone
Number of subjects: 18
Study 29986761 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) group with HRmax > 60%
Number of subjects: 198
Study 29986761 — intervention group
Group type: COMPARATOR
Intervention: Alternative Intervention (AI) group with low-level exercises
Number of subjects: 198
Study 29986761 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list Control (WC) group
Number of subjects: 198
Study 28052887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk (PHM)
Number of subjects: 12
Study 28052887 — intervention group
Group type: COMPARATOR
Intervention: Raw human milk (RHM)
Number of subjects: 12
Study 26258597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume high intensity interval training (HIIT) on cycle ergometer, 3 times a week for 8 weeks (10×60 sec. HIIT)
Number of subjects: 10
Study 26258597 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 10
Study 24194899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (liquid bleach) for household water treatment
Number of subjects: 36
Study 24194899 — intervention group
Group type: COMPARATOR
Intervention: No water treatment (Control)
Number of subjects: 36
Study 21918237 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention arm (n = 58)
Number of subjects: 110
Study 21918237 — intervention group
Group type: COMPARATOR
Intervention: Health and wellness control arm (n = 52)
Number of subjects: 110
Study 18438572 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic retroperitoneal lumbar sympathectomy (Group A)
Number of subjects: 30
Study 18438572 — intervention group
Group type: COMPARATOR
Intervention: No surgical intervention (Group B - control)
Number of subjects: 30
Study 16612489 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodramatic psychotherapy (4 individual and 24 structured group sessions)
Number of subjects: 20
Study 16612489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychodramatic psychotherapy)
Number of subjects: 20
Study 14962145 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary fall-prevention program (experimental ward)
Number of subjects: 825
Study 14962145 — intervention group
Group type: COMPARATOR
Intervention: Current practice (control wards)
Number of subjects: 825
Study 10930900 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole MUPS 20 mg
Number of subjects: 16
Study 10930900 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 16
Study 9200342 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 120
Study 8408666 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent ratings of nausea and emesis
Number of subjects: 33
Study 8408666 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's anxiety and antiemetic regimen
Number of subjects: 33
Study 3542451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insulin above transverse mesocolon (0.2 IU/kg)
Number of subjects: 14
Study 3542451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insulin below transverse mesocolon (0.2 IU/kg)
Number of subjects: 14
Study 3542451 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular insulin (0.2 IU/kg)
Number of subjects: 14
Study 3542451 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (0.2 IU/kg)
Number of subjects: 14
Study 30300037 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural altitude training (NAT)
Number of subjects: 22
Study 30300037 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated live high:train low (SIM)
Number of subjects: 22
Study 30230666 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM) + usual care
Number of subjects: 0
Study 30230666 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 26540248 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care intervention
Number of subjects: 0
Study 26540248 — intervention group
Group type: EXPERIMENTAL
Intervention: Community care intervention
Number of subjects: 0
Study 25364946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga therapy (weekly 1-hour sessions for 8 weeks)
Number of subjects: 50
Study 25364946 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular treatment including daycare rehabilitation program)
Number of subjects: 50
Study 22892463 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual application of silver diamine fluoride (SDF)
Number of subjects: 212
Study 22892463 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-annual application of silver diamine fluoride (SDF)
Number of subjects: 212
Study 22892463 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual application of high fluoride-releasing glass ionomer
Number of subjects: 212
Study 22892463 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 212
Study 20645484 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal-epidural anesthesia and analgesia
Number of subjects: 45
Study 20645484 — intervention group
Group type: COMPARATOR
Intervention: Spinal-intravenous anesthesia and analgesia
Number of subjects: 45
Study 20645484 — intervention group
Group type: COMPARATOR
Intervention: General-intravenous anesthesia and analgesia
Number of subjects: 45
Study 18853995 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 29
Study 18853995 — intervention group
Group type: COMPARATOR
Intervention: Proton-pump inhibitor (PPI) treatment for 8 weeks
Number of subjects: 29
Study 16027336 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 70
Study 16027336 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 70
Study 12647454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 0
Study 12647454 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 11099374 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (6% carbohydrate‐electrolyte)
Number of subjects: 8
Study 11099374 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + Cr+3 (CHO plus chromium picolinate 400 mg)
Number of subjects: 8
Study 11099374 — intervention group
Group type: COMPARATOR
Intervention: P (placebo)
Number of subjects: 8
Study 9278198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(‐1)
Number of subjects: 38
Study 9278198 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 38
Study 8297447 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone (2 x 0.1 mg)
Number of subjects: 22
Study 8297447 — intervention group
Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 22
Study 3026690 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin premedication
Number of subjects: 8
Study 3026690 — intervention group
Group type: COMPARATOR
Intervention: Control (no prazosin)
Number of subjects: 8
Study 30501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 120
Study 30501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 120
Study 30501612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 30501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120
Study 30501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 120
Study 30501612 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 26874885 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1·4 mg/m² intravenously on days 1 and 8)
Number of subjects: 452
Study 26874885 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (850 mg/m², 1000 mg/m², or 1200 mg/m² intravenously on day 1)
Number of subjects: 452
Study 26874885 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 452
Study 26874885 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 452
Study 24303930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-administered, tailored, 1-year telephone-based intervention
Number of subjects: 500
Study 24303930 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study 22828595 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 7320
Study 22828595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7320
Study 20653723 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 7
Study 20653723 — intervention group
Group type: EXPERIMENTAL
Intervention: RCM
Number of subjects: 7
Study 18306248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse management
Number of subjects: 406
Study 18306248 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 406
Study 16401239 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus EGb (n=15)
Number of subjects: 29
Study 16401239 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine alone (n=14)
Number of subjects: 29
Study 12795749 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.i.d, Clarithromycin 500 mg b.i.d, Tinidazole 500 mg b.i.d
Number of subjects: 94
Study 12795749 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg b.i.d, Clarithromycin 500 mg b.i.d, Tinidazole 500 mg b.i.d
Number of subjects: 94
Study 12795749 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.i.d
Number of subjects: 94
Study 12795749 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg b.i.d
Number of subjects: 94
Study 10386189 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH stimulation test
Number of subjects: 15
Study 8712425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) bolus injection of meperidine 0.6 mg/kg and ketorolac 0.5 mg/kg
Number of subjects: 49
Study 8712425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 49
Study 1650106 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (desipramine/petytyl) and incazane
Number of subjects: 0
Study 1650106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemityl (actoprotector)
Number of subjects: 0
Study 1650106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sydnocarb (psychostimulant)
Number of subjects: 0
Study 1650106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (neuroleptic)
Number of subjects: 0